V1a Receptor Agonists
US-2015126432-A1 · May 7, 2015 · US
Treatment of ascites
US9655945B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9655945-B2 |
| Application number | US-201615198050-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 30, 2016 |
| Priority date | Jun 30, 2015 |
| Publication date | May 23, 2017 |
| Grant date | May 23, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a patient diagnosed with ascites due to liver cirrhosis, the method comprising administering terlipressin or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day to the patient for about one day to about 12 months. 2. The method of claim 1 , wherein the continuous terlipressin is administered for about one day to about six months. 3. The method of claim 1 , wherein the continuous terlipressin is administered with an ambulatory infusion pump. 4. The method of claim 1 , wherein the patient has not progressed to hepatorenal syndrome (HRS). 5. The method of claim 1 , wherein the administration of terlipressin is provided on an out-patient basis. 6. The method of claim 1 , wherein the administered dose of terlipressin escalates over the about one day to about 12 months. 7. A method for reducing the accumulation of ascitic fluid in the abdominal cavity in an ambulatory ascites patient, the method comprising administering to the patient terlipressin or salt thereof as a continuous infusion dose of about 1.0 mg to about 12.0 mg per day for about one day to about twelve months with an ambulatory infusion pump. 8. The method of claim 7 , wherein the terlipressin is administered for about one day to about six months. 9. The method of claim 7 , wherein the patient has not progressed to hepatorenal syndrome (HRS). 10. The method of claim 7 , wherein the administration is provided on an out-patient basis. 11. The method of claim 7 , wherein the administered dose of terlipressin escalates over the about one day to about 12 months. 12. The method of claim 1 , wherein patient has not progressed to FIRS type 1. 13. The method of claim 12 , where the patient is not hospitalized. 14. The method of claim 7 , wherein the patient has not progressed to HRS type 1.
Assignees
Inventors
Classifications
Drugs for disorders of the alimentary tract or the digestive system · CPC title
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
Drugs for disorders of the nervous system · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
of the kidneys · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9655945B2 cover?
- A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.
- Who is the assignee on this patent?
- Nanoantibiotics Inc, Univ Degli Studi Padova, Biovie Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K38/095. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).